Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02965950
Other study ID # 2016/816
Secondary ID 2016-003459-31
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 2016
Est. completion date May 2033

Study information

Verified date January 2024
Source Haukeland University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open labeled, phase 2 clinical trial, where patients are stratified to one of two treatment groups based on upfront TP53 mutation status; i.e. TP53 mutated vs. TP53 wt disease, and treated with dose-dense cyclphosphamide. Furthermore, patients included are stratified based on tumor stage; i.e. locally advanced breast cancer (M0 disease) or metastatic breast cancer (M1 disease). All participating cancer centers will prospectively include patients with breast cancer fulfilling the inclusion criteria. If patients do not respond to the experimental treatment as outlined in the protocol, treatment with dose-dense cyclophosphamide will be terminated, and further cancer treatment will continue at the treating oncologist's discretion. The response data for all patients who have received at least one chemotherapy course will be included in the final efficacy analysis. Tumor tissue, blood samples and radiology data will be collected before therapy starts, if therapy needs to be changed, and for patients with locally advanced breast cancer: at surgery. Response data will be evaluated closely during treatment, with clinical assessment of tumor size every two weeks for patients with locally advanced breast cancer and by radiology every eight weeks for patients with metastatic breast cancer. Evaluation of side effects/tolerance will be performed at every clinical visit, i.e. every two weeks for all patients included in the p53 trial.


Description:

Stage IV breast cancer (distant metastases) remains a non-curable condition; thus, treatment is considered palliative. However, many patients may live for years with their metastatic disease with a reasonably good quality of life. As for locally advanced primary breast cancers in need of primary medical therapy, lack of responsiveness to regular chemotherapy is associated with a poor prognosis, with a high risk of relapse and, subsequent, breast cancer death. TP53 mutations have been shown to predict a poor response to anthracyclines, a group of cytotoxic agents which is extensively used and which is in general efficacious in breast cancer. Notably, dose-intensification with cyclophosphamide has been found to significantly improve the response rate in TP53 mutated primary breast cancers. Our preliminary experience indicates that the use of dose-dense cyclophosphamide monotherapy every 2nd week with G-CSF support is well tolerated. As for patients with metastatic disease for whom the alternative would be to receive continuous chemotherapy at 3-weekly intervals the hypothesis is that cyclophosphamide given at 2-weekly intervals over a limited time period, followed by a "treatment holiday" among responders should be associated with a non-inferior quality of life all-over. As for patients with TP53 mutated locally advanced breast cancers where standard chemotherapy fails, the hypothesis is that cyclophosphamide dose dense treatment may be an effective treatment option downstaging the tumor prior to surgery.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 190
Est. completion date May 2033
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Locally advanced breast cancers in need of pre-surgical chemotherapy or metastatic breast cancer in need of chemotherapy. - Resistance to endocrine therapy: Either i) estrogen and progesterone negative tumor, or ii) harboring an estrogen and / or progesterone positive tumor where regular endocrine therapies have failed or where the treating physician finds endocrine therapy not indicated. - Prior cancer therapy: Metastatic disease: First line treatment (amendment 2018): No prior chemotherapy*. Prior endocrine therapy +/- CDK4/6 inhibitor or mTOR inhibitors is allowed if hormone receptor positive, HER2 negative disease. Late-stage disease (approved protocol): i) Prior exposure to and resistance to a taxane regimen**. ii) Prior exposure to and resistance to an anthracycline regimen** -mandatory only for patients with TP53 wt tumors. LABC: i) Prior exposure to and lack of response to to a taxane regimen**. ii) Prior exposure to and lack of response to an anthracycline regimen** - mandatory only for patients with TP53 wt tumors. * Only for patients with TP53 mutated disease. Previous adjuvant chemotherapy, including alkylating agents (cyclophosphamide a.o.) and/or platinum, is allowed if completed >12 months prior to inclusion in the trial. ** In metastatic breast cancer resistance to taxanes/anthracyclines is defined as progressive disease (PD). In LABC lack of response is defined as stable disease (SD) after 4 courses of chemotherapy or PD. Breast cancer relapsing within 12 months subsequent to adjuvant taxanes or anthracyclines is considered resistant and re-exposure is not required prior to inclusion in the trial. This relates also to patients who could not receive proper taxane or anthracycline therapy due to side effects or other medical reasons. - The primary tumor or at least one metastatic lesion must be available for biopsy collection at protocol inclusion. Notably; for patients with primary metastatic breast cancer, TP53 status should be determined in a metastatic deposit; tissue from the primary tumor may not substitute (this relates both to patients with synchronous and metachronous metastatic disease). - Patients must have clinically and/or radiographically documented measurable breast cancer according to RECIST. - WHO performance status 0-1 - Known tumor ER, PGR and HER2 status in the current situation, i.e. archival and historic breast cancer tissue can not be used for patients with relapse of the disease. However, patients can be included regardless of hormone receptor and HER2 status; in case such information lacks at inclusion, it may be analysed on the biopsy retrospectively. - Age >18 years - Radiology studies (CT thorax/abdomen and bone scintigraphy/bone scan) and ecco cor must be performed within 28 days prior to start of treatment. - Before patient registration, written informed consent must be given according to national and local regulations. - Blood test requirements: - Neutrophils > 1.0 x 109/L - Platelets > 75 x 109/L - Bilirubin < 20 µmol/L. - Serum creatinine < 1.5 x ULN Exclusion Criteria: - Co-morbidity that, based on the assessment of the treating physician, may preclude the use of cyclophosphamide at actual doses. - Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial - Pregnant or lactating patients. - Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist. - Active cystitis (to be treated upfront) - Active bacterial infections - Urinary obstruction - Known hypersensitivity towards cyclophosphamide or pegfilgrastim, their metabolites and other ingredients in the drug administration formulation. - Patient not able to give an informed consent or comply with study regulations as deemed by study investigator. - Amendment 2018: Patients with HER2 positive, metastatic breast cancer in the first line setting (Arm C).

Study Design


Intervention

Drug:
Cyclophosphamide
I.v. infusion

Locations

Country Name City State
Norway Haukeland University Hospital Bergen Hordaland
Norway Akershus University Hospital Lørenskog
Norway Stavanger University Hospital Stavanger
Norway University Hospital of Northern Norway Tromsø
Norway St. Olavs Hospital Trondheim Sør Trøndelag

Sponsors (1)

Lead Sponsor Collaborator
Haukeland University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) measured clinically (with calipers) or radiologically per RECIST guidelines. ORR of dose dense cyclophosphamide in patients with TP53 mutated breast cancer or TP53 wt breast cancer. Four years
Secondary Number of patients harboring the same molecular aberration or set of aberrations, and which are associated with either response to treatment or survival. These are genomic and proteomic aberrations beyond TP53 mutations. Four years
Secondary Number of patients harboring the same TP53 mutation subtype Assess whether responses are recorded among patients harbouring TP53 mutations belonging to particular mutation subgroups. Four years
Secondary Number of patients achieving pathological complete response (pCR) Patients achieving pathological complete response (pCR), measured as no remaining infiltrative carcinoma in the breast and axillary nodes by histology, in TP53 wt and mutated subgroups, after dose-dense cyclophosphamide. Four years
Secondary Recurrence-free survival Recurrence-free survival after dose-dense cyclophosphamide. 14 years
Secondary Overall survival Recurrence-free and overall survival after dose-dense cyclophosphamide. 14 years
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Safety and tolerability of dose-dense cyclophosphamide Four years
See also
  Status Clinical Trial Phase
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT02778685 - Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer Phase 2
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Suspended NCT03737695 - Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
Active, not recruiting NCT04316117 - Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study Phase 2
Active, not recruiting NCT02595905 - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Phase 2
Not yet recruiting NCT04529044 - 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Phase 2
Withdrawn NCT06145399 - A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer Early Phase 1
Recruiting NCT04673448 - Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Recruiting NCT05751668 - Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) Phase 2
Suspended NCT04906369 - Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring
Active, not recruiting NCT03281902 - Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Withdrawn NCT04351230 - T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer Phase 2
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Completed NCT04256941 - Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Phase 2
Completed NCT01142401 - Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Phase 2
Terminated NCT04108858 - Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT01351909 - Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Phase 1
Completed NCT06206239 - Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer
Withdrawn NCT04756505 - Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial Phase 1